Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Aug 1;8(8):CD012082.
doi: 10.1002/14651858.CD012082.pub2.

Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews

Patricia M Fortin  1 , Sally Hopewell, Lise J Estcourt
Affiliations
Meta-Analysis

Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews

Patricia M Fortin et al. Cochrane Database Syst Rev. .

Abstract

Background: Globally, sickle cell disease (SCD) is one of the commonest severe monogenic disorders, due to the inheritance of two abnormal haemoglobin (beta globin) genes. SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Red blood cell (RBC) transfusions are used to treat complications of SCD, e.g. acute chest syndrome (ACS) (this often involves a single transfusion episode), or they can be part of a regular long-term transfusion programme to prevent SCD complications.

Objectives: To summarize the evidence in Cochrane Reviews of the effectiveness and safety of RBC transfusions versus no transfusion, or restrictive (to increase the total haemoglobin) versus liberal (to decrease the haemoglobin S level below a specified percentage) transfusion, for treating or preventing complications experienced by people with SCD.

Methods: We included Cochrane Reviews of randomised or quasi-randomised controlled trials published in the Cochrane Database of Systematic Reviews, that addressed various SCD complications and had RBC transfusion as an intervention or comparator. We assessed the methodological quality of included reviews according to the AMSTAR quality assessment.

Main results: We included 15 Cochrane Reviews, 10 of which had no included studies with an RBC transfusion intervention (five reported RCTs with other interventions; and five contained no studies). Five of the 15 reviews included participants randomised to RBC transfusion, but in one of these reviews only 10 participants were randomised with no usable data. Four reviews (nine trials with 1502 participants) reported data comparing short- or long-term RBC transfusions versus standard care, disease-modifying agents, a restrictive versus a liberal transfusion strategy and long-term RBC transfusions versus transfusions to treat complications. All reviews were of high quality according to AMSTAR quality assessment, however, the quality of the included trials was highly variable across outcomes. Trials were downgraded according to GRADE methodology for risk of bias, indirectness (most trials were conducted in children with HbSS), and imprecision (outcomes had wide confidence intervals).In all four reviews and all comparisons there was little or no difference in the risk of death (very low-quality evidence). There were either no deaths or death was a rare event.Short-term RBC transfusion versus standard care (one review: two trials, 434 participants, GRADE very low- to low-quality evidence)In people undergoing low- to medium-risk surgery, RBC transfusions may decrease the risk of acute chest syndrome (ACS) in people with African haplotypes compared to standard care (low-quality evidence), but there was little or no difference in people with the Arabic haplotype (very-low quality evidence). There was also little or no difference in the risk of other SCD-related or transfusion-related complications (very-low quality evidence).Long-term RBC transfusion versus standard care (two reviews: three trials, 405 participants, very low- to moderate-quality evidence)In children and adolescents at high risk of stroke (abnormal transcranial doppler (TCD) velocities or silent cerebral infarct (SCI)), long-term RBC transfusions probably decrease the risk of stroke (moderate-quality evidence) and may decrease the risk of ACS and painful crisis compared to standard care (low-quality evidence). Long-term RBC transfusions may also decrease the risk of SCI in children with abnormal TCD velocities (low-quality evidence), but there may be little or no difference in the risk of SCI in children with normal TCD velocities and previous SCI (low-quality evidence).In children and adolescents already receiving long-term RBC transfusions for preventing stroke, in comparison to standard care, continuing long-term RBC transfusions may reduce the risk of SCI (low-quality evidence) but we do not know whether there is a difference in the risk of stroke (very-low quality evidence). In children with normal TCD velocities and SCI there was little or no difference in the risk of alloimmunisation or transfusion reactions, but RBC transfusions may increase the risk of iron overload (low-quality evidence).Long-term RBC transfusion versus RBC transfusion to treat complications (one review: one trial, 72 participants, very low- to low-quality evidence)In pregnant women, long-term RBC transfusions may decrease the risk of painful crisis compared to transfusion for complications (low-quality evidence); but there may be little or no difference in the risk of other SCD-related complications or transfusion reactions (very-low quality evidence).RBC transfusion versus disease-modifying agents (hydroxyurea) (two reviews: two trials; 254 participants, very low- to low-quality evidence)For primary prevention of stroke in children, with abnormal TCD and no severe vasculopathy on magnetic resonance imaging/magnetic resonance angiography (MRI/MRA), who have received at least one year of RBC transfusions, we do not know whether there is a difference between RBC transfusion and disease-modifying agents in the risk of stroke; SCI; ACS; or painful crisis (very-low quality evidence). There may be little or no difference in the risk of iron overload (low-quality evidence).Similarly, for secondary prevention of stroke in children and adolescents, we do not know whether there is a difference between these interventions in the risk of stroke; SCI; or ACS (very-low quality evidence); but hydroxyurea with phlebotomy may increase the risk of painful crisis and global SCD serious adverse events compared to RBC transfusion (low-quality evidence). There may be little or no difference in the risk of iron overload (low-quality evidence).Restrictive versus liberal RBC transfusion strategy (one review: one trial; 230 participants, very low-quality evidence)In people undergoing cholecystectomy, there was little or no difference between strategies in the risk of SCD-related or transfusion-related complications (very-low quality evidence).

Authors' conclusions: This overview provides support from two high-quality Cochrane Reviews for the use of RBC transfusions in preventing stroke in children and adolescents at high risk of stroke (abnormal TCDs or SCI) and evidence that it may decrease the risk of SCI in children with abnormal TCD velocities. In addition RBC transfusions may reduce the risk of ACS and painful crisis in this population.This overview highlights the lack of high-quality evidence in adults with SCD and the number of reviews that have no evidence for the use of RBC transfusions across a spectrum of SCD complications. Also of concern is the variable and often incomplete reporting of patient-relevant outcomes in the included trials such as SCD-related serious adverse events and quality of life.

PubMed Disclaimer

Conflict of interest statement

Patricia Fortin: funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.

Sally Hopewell: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.

Lise Estcourt: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.

Update of

References

References to included reviews

Chinegwundoh 2004
    1. Chinegwundoh FI, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004198.pub2; CD004198] - DOI - PubMed
Dastgiri 2016
    1. Dastgiri S, Dolatkhah R. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3; CD007843] - DOI - PubMed
Estcourt 2016a
    1. Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Hambleton IR, Cho G. Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD008360.pub4; CD008360] - DOI - PMC - PubMed
Estcourt 2016b
    1. Estcourt LJ, Fortin PM, Trivella M, Hopewell S. Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD003149.pub3; CD003149] - DOI - PMC - PubMed
Estcourt 2017a
    1. Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD003146.pub3; CD003146] - DOI - PMC - PubMed
Estcourt 2017b
    1. Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database of Systematic Reviews 2017, Issue 5. [DOI: 10.1002/14651858.CD012389.pub2; CD012389] - DOI - PMC - PubMed
Martí‐Carvajal 2009
    1. Martí‐Carvajal AJ, Peña‐Martí GE, Comunián‐Carrasco G, Martí‐Peña AJ. Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006786.pub2; CD006786] - DOI - PMC - PubMed
Martí‐Carvajal 2014
    1. Martí‐Carvajal AJ, Knight‐Madden JM, Martinez‐Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD008394.pub3; CD008394] - DOI - PMC - PubMed
Martí‐Carvajal 2015a
    1. Martí‐Carvajal AJ, Simancas‐Racines D. Interventions for treating intrahepatic cholestasis in people with sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010985.pub2; CD010985] - DOI - PubMed
Martí‐Carvajal 2016
    1. Martí‐Carvajal AJ, Solà I, Agreda‐Pérez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/14651858.CD004344.pub6; CD004344] - DOI - PubMed
Okusanya 2016
    1. Okusanya BO, Oladapo OT. Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD010378.pub3; CD010378] - DOI - PMC - PubMed
Oniyangi 2015
    1. Oniyangi O, Cohall DH. Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD004448.pub5; CD004448] - DOI - PubMed
Oringanje 2016
    1. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD007001.pub4; CD007001] - DOI - PMC - PubMed
Owusu‐Ofori 2015
    1. Owusu‐Ofori S, Remmington T. Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD003425.pub3; CD003425] - DOI - PubMed
Roy 2017
    1. Roy NB, Fortin PM, Bull KR, Doree C, Trivella M, Hopewell S, et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database of Systematic Reviews 201, Issue 7. [DOI: 10.1002/14651858.CD012380; CD012380] - DOI - PMC - PubMed

References to excluded reviews

Al Hajeri 2016
    1. Al Hajeri A, Fedorowicz Z. Piracetam for reducing the incidence of painful sickle cell disease crises. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD006111.pub2] - DOI - PMC - PubMed
Alhashimi 2010
    1. Alhashimi D, Fedorowicz Z, Alhashimi F, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007843.pub2] - DOI - PubMed
Carson 2012
    1. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD002042.pub4] - DOI - PMC - PubMed
Dodd 2004
    1. Dodd JM, Dare MR, Middleton P. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004222.pub2] - DOI - PMC - PubMed
Jones 2001
    1. Jones AP, Davies SC, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD002202] - DOI - PubMed
Knight‐Madden 2014
    1. Knight‐Madden JM, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD003733.pub3] - DOI - PubMed
Martí‐Carvajal 2012
    1. Martí‐Carvajal AJ, Conterno LO. Antibiotics for treating community acquired pneumonia in people with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD005598.pub3] - DOI - PubMed
Martí‐Carvajal 2015b
    1. Martí‐Carvajal AJ, Conterno LO, Knight‐Madden JM. Antibiotics for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD006110.pub4] - DOI - PMC - PubMed
Meremikwu 1999
    1. Meremikwu MM, Smith HJ. Blood transfusion for treating malarial anaemia. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD001475] - DOI - PMC - PubMed
Nagalla 2012
    1. Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD003426.pub4] - DOI - PubMed
Okomo 2015
    1. Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD005406.pub4] - DOI - PubMed
van Zuuren 2013
    1. Zuuren EJ, Fedorowicz Z. Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD010155.pub2] - DOI - PubMed

Additional references

Adams 1998
    1. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine 1998;339(1):5‐11. - PubMed
Adams 2005
    1. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine 2005;353(26):2769‐78. - PubMed
Akinsheye 2011
    1. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011;118(1):19‐27. - PMC - PubMed
Akinsulie 2005
    1. Akinsulie AO, Temiye EO, Akanmu AS, Lesi FEA, Whyte CO. Clinical evaluation of extract of Cajanuscajan (Ciklavit) in sickle cell anaemia. Journal of Tropical Paediatrics 2005;51(4):200‐5. - PubMed
Al‐Jaouni 2006
    1. Al‐Jaouni SK, Al‐Muhayawi SM, Qari MH, Nawas MA, Al‐Mazrooa A. Randomized clinical trial to evaluate the safety of avoiding pre‐operative transfusion in sickle cell anemia. Bahrain Medical Bulletin 2006;28(4):164‐7. []
Ansong 2013
    1. Ansong D, Akoto A O, Ocloo D, Ohene‐Frempong K. Sickle cell disease: management options and challenges in developing countries. Mediterranean Journal of Hematology and Infectious Diseases 2013;5(1):e2013062. - PMC - PubMed
Ballard 2017
    1. Ballard M, Montgomery P. Risk of bias in overviews of reviews: a scoping review of methodological guidance and four‐item checklist. Research Synthesis Methods 2017;8:92‐108. [DOI: 10.1002/jrsm.1229] - DOI - PubMed
Balshem 2011
    1. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE Guidelines 3. rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401‐6. - PubMed
Baum 1987
    1. Baum KF, MacFarlane DE, Maude GH, Serjeant GR. Topical antibiotics in chronic sickle cell leg ulcers. Transactions of the Royal Society of Tropical Medicine and Hygiene 1987;81(5):847‐9. - PubMed
Chou 2013a
    1. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology 2013;2013:439‐46. - PubMed
Chou 2013b
    1. Chou ST, Jackson T, Vege S, Smith‐Whiteley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh‐matched minority donors. Blood 2013;122(6):1062‐71. - PubMed
DeBaun 2014
    1. DeBaun MR, M Gordon, RC McKinstry, MJ Noetzel, DA White, SA Sarnaik, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine 2014;371(8):699‐710. - PMC - PubMed
Expert Panel Report 2014
    1. US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute Expert Panel Report 2014. Evidence‐based management of sickle cell disease: Expert Panel Report, 2014. http://www.nhlbi.nih.gov/health‐pro/guidelines/sickle‐cell‐disease‐guide... (accessed 01 August 2015).
Foucan 1998
    1. Foucan L, Bourhis V, Bangou J, Merault L, Etienne‐Julan M, Salmi RL. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. American Journal of Medicine 1998;104(4):339‐42. - PubMed
Frenette 2007
    1. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts and future promise. Journal of Clinical Investigation 2007;117(4):850‐8. - PMC - PubMed
Gravitz 2014
    1. Gravitz L, Pincock S. Sickle‐cell disease. Nature 2014;515(7526):S1. - PubMed
Grosse 2011
    1. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa. A neglected cause of early childhood mortality. American Journal of Preventive Medicine 2011;41(6S4):S398‐S405. - PMC - PubMed
Higgins 2011a
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JPT, Green S (editors). Chapter 22: Overviews of reviews. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Howard 2013
    1. Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet 2013;381:930‐8. - PubMed
Josephson 2007
    1. Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfusion Medicine Reviews 2007;21(2):118‐32. - PubMed
Kato 2006a
    1. Kato GJ, McGowan V, Machado RF, Little JA, Morris CR, et al. Lactate dehydrogenase as a biomarker of hemolysis‐associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107(6):2279‐85. - PMC - PubMed
Kato 2006b
    1. Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology 2006;81(7):503‐10. - PMC - PubMed
Koshy 1988
    1. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red‐cell transfusions in pregnant patients with sickle cell disease. New England Journal of Medicine 1988;319:1447–52. - PubMed
La Grenade 1993
    1. Grenade L, Thomas PW, Serjeant GR. A randomized controlled trial of solcoseryl and duoderm in chronic sickle cell ulcers. West Indian Medical Journal 1993;42(3):121‐3. - PubMed
McMahon 2010
    1. McMahon L, Tamary H, Askin M, Adams‐Graves P, Eberhardt RT, Sutton M, et al. A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. British Journal of Haematology 2010;151(5):526‐24. - PubMed
Neumayr 2006
    1. Neumayr LD, Aguilar C, Earles AN, Jergesen HE, Haberkern CM, Kammen BF, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. Journal of Bone and Joint Surgery 2006;88(12):2573‐82. - PubMed
NICE 2010
    1. NICE (National Institute for Health and Care Excellence). Sickle cell disease. http://cks.nice.org.uk/sickle‐cell‐disease#!backgroundsub:3. London: NICE, (accessed 01 August 2015).
Ohene‐Frempong 1999
    1. Ohene‐Frempong K. Sickle cell disease in the United Statesof America and Africa. Hematology (American Society of Hematology Education Program). American Society of Hematology 1999:64‐72.
Piel 2012
    1. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model‐based map and population estimates. Lancet 2012;381(9861):142‐51. - PMC - PubMed
Piel 2017
    1. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. New England Journal of Medicine 2017;376(16):1561‐73. - PubMed
Pieper 2015
    1. Pieper D, Buechter RB, Li L, Prediger B, Eikermann M. Systematic review found AMSTAR, but not R(evised)‐AMSTAR to have good measurement properties. Journal of Clinical Epidemiology 2015;68:574‐583. - PubMed
Pleasants 2014
    1. Pleasants S. Epidemiology: a moving target. Nature 2014;515(7526):S2‐3. - PubMed
Porter 2013
    1. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. ASH Education Program Book 2013;1:447‐56. - PubMed
Rees 2010
    1. Rees DC, Williams TN, Gladwin MT. Sickle‐cell disease. Lancet 2010;376(9757):2018‐31. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre. Review Manager (RevMan). Version Version 5.3. Copenhagen: The Cochrane Collaboration, 2014.
Rumaney 2014
    1. Rumaney MB, Ngo Bitoungui VJ, VorsterAA, Ramesar R, Kengne AP, Ngogang J, et al. The co‐inheritance of alpha‐thalassemia and sickle cell anemia is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival. PLoS ONE 2014;9(6):e100516. - PMC - PubMed
Scheunemann 2010
    1. Scheunemann LP, Ataga KI. Delayed hemolytic transfusion reaction in sickle cell disease. American Journal of the Medical Sciences 2010;339(3):266‐9. - PMC - PubMed
Schmalzer 1987
    1. Schmalzer EA, Lee JO, Brown AK, Usami S, Chien S. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 1987;27(3):228‐33. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Serjeant 1977
    1. Serjeant GR, Howard C. Isoxsuprine hydrochloride in the therapy of sickle cell leg ulceration. West Indian Medical Journal 1977;26(3):164‐6. - PubMed
Serjeant 1985
    1. Serjeant GR, Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle‐cell disease. Lancet 1985;2(8467):1274‐6. - PubMed
Serjeant 1997
    1. Serjeant BE, Harris J, Thomas P, Serjeant GR. Propionyl‐L‐carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. Journal of the American Academy of Dermatology 1997;37:491‐3. - PubMed
Shea 2007
    1. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007; Vol. 7, issue 10. - PMC - PubMed
Sparkenbaugh 2013
    1. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. British Journal of Haematology 2013;162(1):3‐14. - PMC - PubMed
Steinberg 2012
    1. Steinberg MH, Sebastini P. Genetic modifiers of sickle cell disease. American Journal of Hematology 2012;87(8):795‐803. - PMC - PubMed
Styles 2012
    1. Styles L, Wager CG, Labotka RJ, Smith‐Whitley K, Thompson AA, Lane PA, et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).. British Journal of Haematology 2012;157(5):627‐36. - PMC - PubMed
Swerdlow 2006
    1. Swerdlow PS. Red cell exchange in sickle cell disease. Hematology 2006;2006:48‐53. - PubMed
Ubesie 2012
    1. Ubesie A, Emodi I, Ikefuna A, Ilechukwu G, Ilechukwu G. Prevalence of human immunodeficiency virus transmission among transfused children with sickle cell anemia in Enugu Nigeria. Annals of Medical and Health Sciences Research 2012;2(2):109‐13. - PMC - PubMed
Vichinsky 1995
    1. Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M, et al. A comparison of conservative and aggressive transfusion regimes in the perioperative management of sickle cell disease. New England Journal of Medicine 1995;333(4):206‐13. - PubMed
Wagner 2007
    1. Wagner MH, Berry RB. A patient with sickle cell disease and a low baseline sleeping oxygen saturation. Journal of Clinical Sleep Medicine 2007;3(3):313‐5. - PMC - PubMed
Wambebe 2001
    1. Wambebe C, Khamofu H, Momoh JAF, Ekpeyong M, Audu BS, Njoku OS, et al. Double‐blind, placebo controlled,randomised cross‐over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine 2001;8(4):252‐61. - PubMed
Wang 2011
    1. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide in very young children with sickle cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377(9778):1663‐72. - PMC - PubMed
Ware 2012
    1. Ware RE, Helms RW, SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 2012;119(17):3925‐32. - PMC - PubMed
Ware 2016
    1. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia ‐ TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open‐label, phase 3, non‐inferiority trial. Lancet 2016;387(10019):661‐70. - PMC - PubMed
Ware 2017
    1. Ware RE, Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet 2017;390:311‐23. - PubMed
Wethers 1994
    1. Wethers DL, Ramirez GM, Koshy M, Steinberg MH, Phillips G Jr, Siegel RS, et al. Accelerated healing of chronic sickle‐cell leg ulcers treated with RGD peptide matrix. RGD Study Group. Blood 1994;84(6):1775‐9. - PubMed
Yawn 2014
    1. Yawn BP, Buchanan GR, Afenyi‐Annan AN, Ballas SK, Hassel KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members. JAMA 2014;312(10):1033‐48. - PubMed
Zorzela 2016
    1. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ 2016;352:i157. - PubMed

Publication types

LinkOut - more resources